Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study

被引：0
|
作者：
Altena, R. [1 ]
Tzortzakakis, A. [2 ,3 ]
Blomgren, A. [2 ]
Jussing, E. [4 ]
Ekman, S. [5 ]
Tran, T. [4 ]
Axelsson, R. [6 ]
Bergh, J. [7 ]
机构：
[1] Karolinska Univ Hosp, Breast Endocrine Tumors & Sarcoma, Solna, Sweden
[2] Karolinska Univ Hosp, Nucl Med, Stockholm, Sweden
[3] Karolinska Inst Huddinge, Stockholm, Sweden
[4] Karolinska Inst, Radiopharm, Huddinge, Sweden
[5] Karolinska Univ, Dept Oncol, Hosp Solna, Solna, Sweden
[6] Karolinska Inst, MMK, Stockholm, Sweden
[7] Karolinska Inst, Oncol Pathol Dept, Bioclin, Solna, Sweden
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.382
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435TiP
引用
收藏
页码：S402 / S403
页数：2
相关论文
共 20 条
  • [1] Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
    Botti, Gerardo
    Collina, Francesca
    Scognamiglio, Giosue
    Rao, Federica
    Peluso, Valentina
    De Cecio, Rossella
    Piezzo, Michela
    Landi, Gabriella
    De Laurentiis, Michelino
    Cantile, Monica
    Di Bonito, Maurizio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (02)
  • [2] Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer
    Hughes, Daniel Johnathan
    Josephides, Eleni
    O'Shea, Robert
    Manickavasagar, Thubeena
    Horst, Carolyn
    Hunter, Sarah
    Taniere, Philippe
    Nonaka, Daisuke
    Van Hemelrijck, Mieke
    Spicer, James
    Goh, Vicky
    Bille, Andrea
    Karapanagiotou, Eleni
    Cook, Gary J. R.
    EUROPEAN RADIOLOGY, 2024, 34 (9) : 5889 - 5902
  • [3] Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
    Noske, Aurelia
    Wagner, Daniel-Christoph
    Schwamborn, Kristina
    Foersch, Sebastian
    Steiger, Katja
    Kiechle, Marion
    Oettler, Dirk
    Karapetyan, Siranush
    Hapfelmeier, Alexander
    Roth, Wilfried
    Weichert, Wilko
    BREAST, 2021, 60 : 238 - 244
  • [4] Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells
    Pimentel, Julio M.
    Zhou, Jun-Ying
    Wu, Gen Sheng
    MOLECULAR CARCINOGENESIS, 2023, 62 (02) : 135 - 144
  • [5] ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD--L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
    Hegi-Johnson, Fiona
    Rudd, Stacey E.
    Wichmann, Christian
    Akhurst, Tim
    Roselt, Peter
    Trinh, Jenny
    John, Thomas
    Devereux, Lisa
    Donnelly, Paul S.
    Hicks, Rod
    Scott, Andrew M.
    Steinfort, Daniel
    Fox, Stephen
    Blyth, Benjamin
    Parakh, Sagun
    Hanna, Gerard G.
    Callahan, Jason
    Burbury, Kate
    MacManus, Michael
    BMJ OPEN, 2022, 12 (11):
  • [6] Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC)
    Noske, A.
    Wagner, D-C.
    Schwamborn, K.
    Foersch, S.
    Steiger, K.
    Kiechle, M.
    Karapetyan, S.
    Oettler, D.
    Hapfelmeier, A.
    Roth, W.
    Weichert, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S26 - S26
  • [7] Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC).
    Tung, Nadine M.
    Garber, Judy Ellen
    Torous, Vanda
    Hacker, Michele R.
    Freeman, Gordon James
    Rodig, Scott J.
    Poles, Emily
    Alexander, Brian Michael
    Lee, Larissa Janeen
    Collins, Laura C.
    Schnitt, Stuart J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
    Azim, Hamdy A.
    Shohdy, Kyrillus S.
    Elghazawy, Hagar
    Salib, Monica M.
    Almeldin, Doaa
    Kassem, Loay
    BIOMARKERS, 2022, 27 (08) : 764 - 772
  • [9] 89Zr-Trastuzumab-DM1: A Novel Probe for Positron-Emission Tomography (PET) Imaging of the Delivery of T-DM1 (Kadcyla) to HER2-Positive Breast Cancer
    Al-Saden, N.
    Reilly, R.
    Chan, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S448 - S448
  • [10] Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab A Pilot Clinical Translation Study
    Wang, Shujing
    Zhu, Hua
    Ding, Jin
    Wang, Feng
    Meng, Xiangxi
    Ding, Lixin
    Zhang, Yan
    Li, Nan
    Yao, Sheng
    Sheng, Xinan
    Yang, Zhi
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (05) : 382 - 388
12